StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie other Neuroscience — International reported growth YoY (%) (%)

Form 8-K Key Product Revenues Schedule

QuarterlyAnnual
Latest, Q2 2026
-8.9%
Period ended Jun 30, 2026
Change on a year earlier
+14.4 pts
-23.3% in Q2 2025
History
16 quarters
Since Q3 2021
Sources
16
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther Neuroscience — International reported growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-8.9%+14.4 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 2026-1.5%-0.5 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 2025-20.1%–Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202592.3%–Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 2025-23.3%–Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 2025-1.0%–Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2023Dec 31, 202361.7%+70.5 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 20236.2%-4.0 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20234.7%-4.9 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20236.9%-4.5 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022-8.8%-50.8 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 202210.2%+22.3 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗
Q2 2022Jun 30, 20229.6%–Form 8-K (abbv-20220630xexhibit991.htm, filed 2022-07-29) ↗
Q1 2022Mar 31, 202211.4%–Form 8-K (abbv-20220331xexhibit991.htm, filed 2022-04-29) ↗
Q4 2021Dec 31, 202142.0%–Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
Q3 2021Sep 30, 2021-12.1%–Form 8-K (abbv-20210930xexhibit991.htm, filed 2021-10-29) ↗

Cite this data

StockData. (2026). AbbVie Other Neuroscience — International reported growth YoY (%) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/other_neuro_intl_rep_yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.